文献速递泌尿生殖技术与安全MR

晚期肾功能障碍患者使用钆基对比剂后发生肾源性系统性纤维化

Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents.
PubMed 文献 · Radiology · 2025-01-01

该研究基于TriNetX美国网络回顾性纳入2010年1月至2025年1月接受钆基对比剂的73 022例晚期慢性肾脏病或终末期肾病患者,经倾向性评分匹配后,可能肾源性系统性纤维化的诊断编码率在患者组与无肾功能障碍对照组间无显著差异(RR 1.00,95%CI 0.63–1.59,P > .99)。

要点

  • 晚期慢性肾脏病或终末期肾病患者使用现代钆基对比剂后,可能肾源性系统性纤维化的诊断编码率极低(0.05%)。
  • 匹配后患者组与无肾功能障碍对照组的可能肾源性系统性纤维化编码率无显著差异(RR 1.00,95%CI 0.63–1.59,P > .99)。
  • 接受美国放射学会II组或大环类钆基对比剂的患者,其诊断编码率与对照组相似。

核心结论

  • 在真实世界数据库分析中,晚期慢性肾脏病或终末期肾病患者接受现代钆基对比剂后出现可能肾源性系统性纤维化诊断编码的概率极低,且不显著高于无肾功能障碍的匹配对照组。

研究设计与样本

  • 回顾性研究,从TriNetX美国网络识别2010年1月至2025年1月接受钆基对比剂的成人晚期慢性肾脏病或终末期肾病患者73 022例,并进行倾向性评分匹配以对照组减少混杂。

诊断标准与关键数值

  • 主要终点为1年内可能肾源性系统性纤维化(ICD-10编码L90.8),匹配后患者组36例(0.05%)vs 对照组36例(0.05%),RR 1.00(95%CI 0.63–1.59),P > .99。
  • 次要终点为可能肾源性系统性纤维化混杂因素编码,匹配后患者组542例(0.74%)vs 对照组518例(0.71%),RR 1.05(95%CI 0.93–1.18),P = .46。
  • 接受美国放射学会II组钆基对比剂和大环类钆基对比剂的患者,诊断编码率与无晚期慢性肾脏病或终末期肾病的对照组相似,无差异证据。

临床应用与阅片要点

  • 在晚期慢性肾脏病或终末期肾病患者中,使用现代钆基对比剂后可能肾源性系统性纤维化的诊断编码率极低且与对照无显著差异,原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The risk of nephrogenic systemic fibrosis (NSF) following administration of contemporary gadolinium-based contrast agents (GBCAs) in patients with advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) is thought to be low; however, existing reports have involved relatively few participants compared with the number of patients who might benefit from contrast-enhanced MRI in the United States. Purpose To estimate the risk of NSF with contemporary GBCAs in real-world practice in patients with advanced CKD or ESRD. Materials and Methods Adult patients with preexisting diagnoses of stage 4 or 5 CKD or ESRD who received GBCAs between January 2010 and January 2025 were identified retrospectively from the TriNetX U.S. Network. Propensity score matching (PSM) with a control group regarding demographic characteristics and comorbidities was performed to reduce confounding. The primary endpoint (possible NSF [International Statistical Classification of Diseases and Related Health Problems, 10th Revision, code L90.8]) and secondary endpoint (possible NSF confounders) were assessed within 1 year. Risk ratios (RRs) were calculated to assess the occurrence and mortality rates of possible NSF, and the Kaplan-Meier log-rank test was used to compare cumulative occurrence rates. Results A total of 73 022 adults (mean age, 64.1 years ± 15.1 [SD]; 39 359 [53.9%] male) with advanced CKD or ESRD who received GBCAs were identified. After PSM, 36 (0.05%) and 542 (0.74%) patients with advanced CKD or ESRD with possible NSF and NSF confounder codes, respectively, were retained, compared with 36 (0.05%) and 518 (0.71%) in controls, respectively (RR, 1.00 [95% CI: 0.63, 1.59] [P > .99] and 1.05 [95% CI: 0.93, 1.18] [P = .46]). Diagnostic code rates were similar for patients who received American College of Radiology group II GBCAs and macrocyclic GBCAs, with no evidence of a difference from those of the controls without advanced CKD or ESRD. Conclusion In this real-world database analysis, the probability of a diagnostic code for possible NSF following contemporary GBCA administration in patients with advanced CKD or ESRD was exceedingly low and not significantly greater than that of matched controls without renal dysfunction. © The Authors 2025. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Li in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Mallepally A, Kidd JM, Grizzard JD, et al. Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents. Radiology. 2025. PMID: 41400469. doi:10.1148/radiol.251794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。